Publications

5491 Results

Adjuvant everolimus in patients with completely resected very high-risk renal cell cancer and clear cell histology: results from the phase III placebo-controlled SWOG S0931 (EVEREST) trial

Authors
P Lara;C Tangen;E Heath;S Gulati;M Stein;M Meng;A Alva;S Pal;I Puzanov;J Clark;T Choueiri;N Agarwal;R Uzzo;N Haas;T Synold;M Plets;U Vaishampayan;B Shuch;S Lerner;I Thompson;C Ryan
Journal / Conference
European Urology May 28:S0302-2838(24)02383-2
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID38811313
Study Number(s)
S0931

A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis

Authors
P Hagen;S Sidana;T Parker;A Hoering;V Sanchorawala;J Zonder;T Kourelis;A DSouza;H Landau;A Rosenthal;S Ailawadhi;R Orlowski;B Walker
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS7575)
Year
2024
Research Committee(s)
Myeloma
Study Number(s)
S2213

Effects of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes: Primary Results from the Randomized Phase III Double-Blind Clinical Trial (S1600)

Authors
J Hamilton-Reeves;J Unger;J Holzbeierlein;DL Lew;J Mark;S Daneshmand;J Kukreja;E Lee;W Tabayoyong;D Hershman;M Fisch;NL Henry
Journal / Conference
J Clin Oncol 42, 2024 (suppl 16; abstr 4501); ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), oral presentation, oral abstract session
Year
2024
Research Committee(s)
Symptom Control and Quality of Life
Study Number(s)
S1600

Impact of the COVID-19 Pandemic on Data Quality in Cancer Treatment Trials: A Meta-Analysis of Sponsor-Level Aggregate Data

Authors
J Unger;H Andrews;L Levit;B McKelvey;M Stewart;E Dressler;K Flaherty;P Fredette;H (L) Jones;T Miller;A Onitilo;T Patel;S Bruinooge;L Garrett-Mayer;C Schenkel
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr 11021)
Year
2024
Research Committee(s)
Cancer Care Delivery

Patient-reported fatigue and risk of treatment-related adverse events (AEs) in patients receiving systemic therapy in cancer clinical trials

Authors
J Unger;R Vaidya;M Fisch;S Jones;NL Henry;D Hershman
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), Rapid Oral Abstract;J Clin Oncol 42, 2024 (suppl 16; abstr 11015)
Year
2024
Research Committee(s)
Symptom Control and Quality of Life

Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-) node-positive breast cancer

Authors
L Pusztai;J Hoag;K Albain;W Barlow;S Stemmer;A Meisner;G Hortobagyi;S Shak;D Hayes;J Rae;R Baehner;P Sharma;K Kalinsky
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), oral; J Clin Oncol 42, 2024 (suppl 16; abstr 508)
Year
2024
Research Committee(s)
Breast
Study Number(s)
S1007, SWOG-8814

EAY191-A6: FOLFOX in Combination with Binimetinib as 2nd-Line Therapy for Patients with Advanced Biliary Tract Cancers (BTCs) with MAPK Pathway Alterations: A ComboMATCH Treatment Trial

Authors
A Shergill;C Liao;M Elsaid;T Al Baghdadi;Y Ji;D Feldman;S George;E O'Reilly;J Meyerhardt;S Berg;G Schwartz;P Munster;T Bekail-Saab;G Abou-Alfa;R Shroff;G Shapiro
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster;J Clin Oncol 42, 2024 (suppl 16; abstr TPS4196)
Year
2024
Research Committee(s)
Gastrointestinal

Impact of GABA pathway genes expression on first-line treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance)

Authors
F Battaglin;Y Yang;J Millstein;S Soni;S Algaze;K Ashouri;P Mittal;P Jayachandran;A Wong;J Lo;L Torres-Gonzalez;W Zhang;F Ou;A Venook;F Innocenti;S Mumenthaler;H-J Lenz
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster;J Clin Oncol 42, 2024 (suppl 16; abstr 3588)
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Risk Prediction Model for Acute Care Use Among Advanced Cancer Patients on Clinical Trials

Authors
D Hershman;C Till;R Vaidya;M LeBlanc;J Unger
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr 11074)
Year
2024
Research Committee(s)
Cancer Care Delivery

Upstream regulation of neurotransmitter signaling genes in metastatic colorectal cancer (mCRC) patients: data from CALGB/SWOG 80405 trial (Alliance) and MONSTAR-SCREEN-2

Authors
J Millstein;F Battaglin;Y Yang;S Soni;S Algaze;P Jayachandran;K Ashouri;P Mittal;L Torres-Gonzalez;W Zhang;F Ou;A Venook;F Innocenti;S Mumenthaler;T Hashimoto;T Fugisawa;Y Nakamura;H Bando;T Yoshino;H-J Lenz
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster;J Clin Oncol 42, 2024 (suppl 16; abstr 3523)
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405